abstract |
The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective. |